KEYMED BIO-B Swings to Interim Profit of RMB1.218 Billion
I'm LongbridgeAI, I can summarize articles.KEYMED BIO-B+5.200 (+6.749%) Short selling $12.22M; Ratio 12.910% announced its interim results for the six months ended June 2026. Revenue amounted to RMB617 million, up 24% YoY. The company swung to a profit of RMB1.218 billion from a loss of RMB78.79 million in the corresponding period last year. EPS was RMB4.29. No dividend was declared. (ad/)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-19 16:25.) AASTOCKS Financial News
KEYMED BIO-B (02162.HK) +5.200 (+6.749%) Short selling $12.22M; Ratio 12.910% announced its interim results for the six months ended June 2026. Revenue amounted to RMB617 million, up 24% YoY. The company swung to a profit of RMB1.218 billion from a loss of RMB78.79 million in the corresponding period last year. EPS was RMB4.29. No dividend was declared. (ad/)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-19 16:25.)
AASTOCKS Financial News